NASH/MASH is a condition with an increased amount of fat, inflammation, and scarring (fibrosis) in the liver. Akero Therapeutics, Inc. (the Sponsor) is running a research study to see if an investigational study drug, efruxifermin (EFX), will help in the treatment of NASH/MASH and liver fibrosis. There are currently no approved medications for the treatment of NASH/MASH.
The study will have 3 groups of subjects who will receive either EFX or placebo. The group you are in will be selected at random. Two out of every three people in the study will receive study drug. One out of three people will receive placebo.
· Be between 18 - 80 years of age
· Have a history or presence of Type 2 diabetes; or
· Have 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose)
· Have a BMI of 25 and greater
· FibroScan® measurement > 8.5 kPa
· Biopsy-proven NASH with fibrosis or are willing to undergo a liver biopsy (Or have a historical biopsy within 180 days)
· Meet additional eligible criteria